These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 1708317)

  • 81. Diagnostic pitfall; interpretation of CA 19-9 concentrations in the presence of hepatic dysfunction.
    Pearce S; Thornes H; Carr D; Tanner A
    Gut; 1994 May; 35(5):707-8. PubMed ID: 8200572
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Serum DU-PAN-2 in the differential diagnosis of pancreatic cancer: influence of jaundice and liver dysfunction.
    Fabris C; Malesci A; Basso D; Bonato C; Del Favero G; Tacconi M; Meggiato T; Fogar P; Panozzo MP; Ferrara C
    Br J Cancer; 1991 Mar; 63(3):451-3. PubMed ID: 2003987
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Tumoral markers and acute-phase reactants in the diagnosis of pancreatic cancer].
    Irigoyen Oyarzabal AM; Amiguet García JA; López Vivanco G; Genollá Subirats J; Muñoz Villafranca MC; Ojembarrena Martínez E; Liso Irurzun P
    Gastroenterol Hepatol; 2003 Dec; 26(10):624-9. PubMed ID: 14670235
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Comparative study of CA-50 (time-resolved fluoroimmunoassay), Span-1, and CA19-9 in the diagnosis of pancreatic cancer.
    Kobayashi T; Kawa S; Tokoo M; Oguchi H; Kiyosawa K; Furuta S; Kanai M; Homma T
    Scand J Gastroenterol; 1991 Jul; 26(7):787-97. PubMed ID: 1896821
    [TBL] [Abstract][Full Text] [Related]  

  • 85. An assessment of the clinical usefulness of two serum markers, CA15 3 and HMFG 2 in localized and metastatic breast cancer.
    Bliss P; Fisken J; Roulsten J; Leonard RC
    Dis Markers; 1993 Jun; 11(1):45-8. PubMed ID: 8358965
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Oxygen derived free radicals in patients with chronic pancreatic and other digestive diseases.
    Basso D; Panozzo MP; Fabris C; del Favero G; Meggiato T; Fogar P; Meani A; Faggian D; Plebani M; Burlina A
    J Clin Pathol; 1990 May; 43(5):403-5. PubMed ID: 1695229
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Co-expression of X-hapten-like antigen and antigen YH206 on mucin molecules.
    Hinoda Y; Imai K; Ban T; Itoh F; Yachi A
    Gastroenterol Jpn; 1991 Feb; 26(1):56-61. PubMed ID: 1706671
    [TBL] [Abstract][Full Text] [Related]  

  • 88. High sensitivity and specificity of CA 19-9 for pancreatic carcinoma in comparison to chronic pancreatitis. Serological and immunohistochemical findings.
    Safi F; Roscher R; Bittner R; Schenkluhn B; Dopfer HP; Beger HG
    Pancreas; 1987; 2(4):398-403. PubMed ID: 3306667
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Evaluation of serum CA 19-9 in malignant tumors.
    Ding HJ; Wu CC; Yang CC; Her SS; Wu LL; Ker CG; Huang TJ
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1987 Jun; 3(6):400-6. PubMed ID: 2838648
    [No Abstract]   [Full Text] [Related]  

  • 90. Biochemical and immunological properties of the human carcinoma antigen CAR-5 defined by the monoclonal antibody BD-5.
    Prat M; Medico E; Garrino C; Comoglio PM
    Int J Cancer; 1989 Jul; 44(1):67-74. PubMed ID: 2473039
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Comparison of two sialosyl-Tn binding monoclonal antibodies (MLS102 and B72.3) in detecting pancreatic cancer.
    Ching CK; Holmes SW; Holmes GK; Long RG
    Gut; 1993 Dec; 34(12):1722-5. PubMed ID: 8282261
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Clinical relevance of tumour markers CA 19-9 and CA-50 in sera from patients with pancreatic duct carcinoma.
    Von Rosen A; Linder S; Harmenberg U; Wiechel KL
    Surg Oncol; 1992 Apr; 1(2):109-13. PubMed ID: 1341241
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Clinical utility of the serum CA 19-9 test for diagnosing pancreatic carcinoma in symptomatic patients: a prospective study.
    Malesci A; Montorsi M; Mariani A; Santambrogio R; Bonato C; Bissi O; Tacconi M; Wizemann G; Spina G
    Pancreas; 1992; 7(4):497-502. PubMed ID: 1641392
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Preparation of pancreatic cancer-associated mucin expressing CA19-9, CA50, Span-1, sialyl SSEA-1, and Dupan-2.
    Kawa S; Kato M; Oguchi H; Kobayashi T; Furuta S; Kanai M
    Scand J Gastroenterol; 1991 Sep; 26(9):981-92. PubMed ID: 1682994
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Usefulness of novel tumour markers.
    Rhodes JM
    Ann Oncol; 1999; 10 Suppl 4():118-21. PubMed ID: 10436801
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Differential diagnosis of pancreatic cancer and chronic pancreatitis by a monoclonal antibody detecting a new cancer-associated antigen (CA 19-9).
    Malesci A; Tommasini MA; Bocchia P; Zerbi A; Beretta E; Vecchi M; Di Carlo V
    Ric Clin Lab; 1984; 14(3):303-6. PubMed ID: 6522955
    [No Abstract]   [Full Text] [Related]  

  • 97. Value of CA 19-9 assay in serum and duodenal juice in the differential diagnosis of pancreatic disease.
    Tappero G; Piantino P
    Int J Biol Markers; 1987; 2(3):191-6. PubMed ID: 3482662
    [TBL] [Abstract][Full Text] [Related]  

  • 98. An initial appraisal of the value of serum carbohydrate antigenic determinant (CA 19-9) levels in patients with pancreatic cancer.
    Buamah PK; Cornell C; Venables CW; Skillen AW
    Eur J Cancer Clin Oncol; 1987 Jan; 23(1):87-91. PubMed ID: 2439345
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Differences in expression of SPan-1 and CA15-3 antigens in blood and tissues.
    Ho JJ; Chung YS; Yuan M; Henslee JG; Kim YS
    Int J Cancer; 1992 Nov; 52(5):693-700. PubMed ID: 1428228
    [TBL] [Abstract][Full Text] [Related]  

  • 100. CA-50 in patients with pancreatic disease--an evaluation of three different laboratory techniques.
    Masson P; Pålsson B; Andren-Sandberg A
    Scand J Clin Lab Invest; 1988 Dec; 48(8):751-5. PubMed ID: 3070717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.